Lead Sponsor

Bukwang Pharmaceutical

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

No

•HBV DNA \> 2,000 copies/mL at screening
•Patients who have compensated liver disease (Child-Pugh score =\<6)
•Patients without LMV resistant mutation by RFMP assay
•Patients who have NOT experienced viral breakthrough at consecutive two measurements (at least one month apart) during lamivudine monotherapy
•Patients who can submit the written consent and comply with the claims postulated of this clinical trial

•Currently receiving antiviral except LMV or corticosteroid therapy
•Patients that previously received antiviral treatment for hepatitis B other than lamivudine in the proceeding 12 months
•Previous treatment with interferon or other immunomodulatory therapies must have ended at least 6 months preceding the study screening
•Treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period
•Patients who is co-infected with HCV, HDV or HIV
•Serious concurrent medical conditions
•Prior organ transplantation
•Patient has creatinine clearance less than 60mL/min as estimated by the following formula:
•\[(140-age in years) (body weight \[kg\])\] / \[(72) (serum creatinine\] \[mg/dL\])\[Note: multiply estimates by 0.85 for women\]

Related studies

NCT06092333 · Chronic Hepatitis B

NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis

NCT02932150 · Chronic Hepatitis B

NCT07343778 · Chronic Hepatitis B With Hepatic Fibrosis

NCT06671093 · Chronic Hep B, Chronic Hepatitis b, and more

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients